Sivik Global Healthcare Llc bought 60,000 shares as the company's stock declined 11.63% while stock markets rallied. Alexion Pharmaceuticals updated its FY17 guidance to $5.50-5.65 EPS.
Other institutional investors also recently made changes to their positions in the company. (NASDAQ:ALXN) shares were sold by PARVEN ALVIN S. HANTSON LUDWIG also bought $1.17 million worth of Alexion Pharmaceuticals, Inc. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company's stock worth $2,424,428,000 after buying an additional 1,298,185 shares in the last quarter. BB&T Securities LLC boosted its position in shares of Alexion Pharmaceuticals by 7.5% in the first quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company's stock valued at $656,000 after acquiring an additional 4,861 shares during the last quarter. State Street Corp grew its position in shares of Alexion Pharmaceuticals by 5.0% during the 2nd quarter. Rampart Invest Management has 0.13% invested in Alexion Pharmaceuticals, Inc. Finally, Dodge & Cox acquired a new position in shares of Alexion Pharmaceuticals during the first quarter valued at about $253,000. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company's stock worth $407,573,000 after buying an additional 64,800 shares in the last quarter.
A number of equities analysts have commented on ALXN shares. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, November 1st. Royal Bank Of Canada upped their price target on shares of Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Stifel Nicolaus decreased their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a "buy" rating for the company in a research note on Tuesday, October 24th. Oppenheimer Holdings, Inc. upgraded shares of Alexion Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $175.00 price objective for the company in a research report on Friday, July 28th. They set a "buy" rating and a $164.00 price target for the company. TheStreet downgraded shares of Alexion Pharmaceuticals from a "b-" rating to a "c+" rating in a research report on Friday.
Hawaiian Airlines to Hold Open Houses for Displaced Island Air Workers
Hawaian Airlines also announced job fairs set for Līhu'e on November 15 and Kahului on November 16. Another partner in the airline industry is inviting Island Air workers to join their team.
In other news, Director Ann M. Veneman sold 835 shares of the firm's stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company's stock, valued at $799,038.80. Following the transaction, the chief executive officer now owns 189,266 shares of the company's stock, valued at approximately $25,955,939.24. The disclosure for this sale can be found here. BB&T Securities LLC now owns 6,254 shares of the biopharmaceutical company's stock valued at $870,000 after buying an additional 438 shares in the last quarter. Insiders own 4.35% of the company's stock. The Japan-based Nippon Life Insurance Co has invested 0.02% in Alexion Pharmaceuticals, Inc.
The stock decreased 1.03% or $1.2 on November 10, reaching $115.17. The company had a trading volume of 1,620,000 shares, compared to its average volume of 2,289,474. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $149.34. The stock has a market capitalization of $25,350.00, a P/E ratio of 23.55, a price-to-earnings-growth ratio of 1.25 and a beta of 1.22. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to analysts' expectations of $864.34 million. During the same quarter in the prior year, the business posted $1.23 EPS. The business's quarterly revenue was up 19.9% compared to the same quarter a year ago. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of USA & global copyright & trademark law. The legal version of this piece can be read at https://stocknewstimes.com/2017/11/13/alexion-pharmaceuticals-inc-alxn-posts-earnings-results-beats-estimates-by-0-12-eps.html. $97,511 worth of Alexion Pharmaceuticals, Inc. The Company's product line includes new and remanufactured automotive hard parts, such as alternators, starters, fuel pumps, water pumps, brake system components, batteries, belts, hoses, temperature control, chassis parts, driveline parts and engine parts; maintenance items, such as oil, antifreeze, fluids, filters, wiper blades, lighting, engine additives and appearance products, and accessories, such as floor mats, seat covers and truck accessories. The Company's products include Soliris, Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
- Will resign if CM asks me to step down: Chandy
- Johnny Depp rejoint l'affiche du Hellfest 2018
- Pour 300 millions d'euros, HSBC solde ses litiges avec la France
- Sri Lanka dream of first-ever Test victory on Indian soil
- German economy expands faster in third quarter
- Aerobic Exercise Can Help Preserve Brain Area Key to Memory
- Joe Jackson Posts Bizarre Video to Grandson Blanket
- Sock defeats Cilic to maintain semis push
- Les femmes au centre de la Journée mondiale du diabète mardi
- Silver Alert declared for missing Terre Haute woman